Objective: To establish the frequency of the c.301_302 delAG mutation of the PROP1 gene in Romanian patients with multiple pituitary hormone deficiency (MPHD).
Subjects And Methods: Somatic assessment, hormonal test, bone age, magnetic resonance imaging of the pituitary gland, and molecular diagnosis were performed in 26 patients with MPHD (7 patients with familial form of MPHD and 19 patients with sporadic form of MPHD).
Results: The c.301_302delAG mutation was detected in the homozygous state in 10 patients belonging to 5 unrelated families (7 patients with familial history of MPHD and 3 patients with sporadic form of MPHD). Those 10 patients presented variable pituitary hormone deficiency and pituitary morphology.
Conclusions: The c.301_302delAG homozygous genotype had a high frequency of 38% (10/26), reaching 100% (7/7) in group with familial cases of MPHD and 16% (3/19) in group with sporadic forms of MPHD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/jpem-2014-0289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Markers of Fertility in Adolescents With Chronic Endocrinopathies at Transition From Paediatric to Adult Care.
Endocrinol Diabetes Metab
July 2024
Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics, University Hospital Heidelberg, Heidelberg, Germany.
Objective: During the process of transition from paediatric to adult health care, counselling concerning fertility is an important issue and is based mainly on serum markers of gonadal function. Here, we analysed these markers in adolescents with various underlying endocrine diseases at the time of transition.
Methods: After reaching near adult height and late puberty (girls: bone age [BA] ≥14 years, and boys: BA ≥16 years), we assessed stages of puberty according to Tanner and measured testes or ovarian volumes and serum markers of gonadal function (anti-Mullerian hormone [AMH], inhibin B, 17β-estradiol, testosterone).
Optimal final adult height achieved by low-dose recombinant human growth hormone therapy.
Asian Biomed (Res Rev News)
April 2024
Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Background: Thailand has been administering the recombinant human growth hormone (rhGH) treatment for >20 years. Due to limited resources being available, efforts have been directed toward utilizing rhGH at the lowest feasible dose. However, there is currently a lack of evidence in terms of the efficacy and outcomes.
View Article and Find Full Text PDFBeyond the bias! Sex distribution in paediatric growth hormone deficiency reexamined.
Clin Endocrinol (Oxf)
May 2024
Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
Objectives: Various biases pertaining to stature account for a male sex predominance in growth hormone deficiency (GHD) cases diagnosed by endocrinology clinics. This manuscript will assess the sex distribution when biases are minimised.
Methods: Retrospective chart review was conducted on patients diagnosed with GHD between 3 and 16 years of age.
[Long-term follow-up data of patients with Multiple Pituitary Hormone Deficiency].
Andes Pediatr
December 2023
Department of Pediatric Endocrinology, Dr. Sami Ulus Obstetrics and Gynecology, Children's Health and Disease Training and Research Hospital, Ankara, Turkey.
Unlabelled: The deficiency of two or more pituitary hormones is called multiple pituitary hormone deficiencies (MPHD). Its prevalence is estimated to be about 1/8,000 worldwide.
Objective: To present the diagnosis processes, clinical findings, and long-term follow-up of patients with MPHD.
Longitudinal assessment of bone health index as a measure of bone health in short-statured children before and during treatment with recombinant growth hormone.
J Pediatr Endocrinol Metab
September 2023
Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics, University Hospital Heidelberg, Heidelberg, Germany.
Article Synopsis
- The study aimed to evaluate bone health index (BHI) changes in short-statured children receiving growth hormone (GH) treatment over a long period.
- A total of 256 children with various conditions related to short stature were assessed using radiographs to track their bone health before and after starting GH therapy from 2010 to 2018.
- The results showed that while BHI was initially low in these children, it improved significantly after one year of GH treatment and continued to show sustained improvement over time, indicating better bone health.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!